Media Contact:
Stephen Majors
Head of Global Communications
smajors@alliancerm.org
Brussels, BE
The new EU Joint Clinical Assessment (JCA) will become an additional barrier for patient access to transformative advanced therapies if the HTA Coordination Group does not modernize its approach to evaluating these medicines, warned 30 not-for-profit organisations, including patient groups, scientific societies, research foundations and medical institutes, in a Call to Action.
San Diego, CA
This landmark partnership seeks to bolster efforts in aligning regulatory frameworks between the United States and Korea and jointly monitoring and reporting on trends within the field.
Brussels, BE
The EU Health Technology Assessment (HTA) Coordination Group’s ‘Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons’ is discouraging news for rare disease patients and the Advanced Therapy Medicinal Products (ATMP) sector.
Washington, DC
The voluntary model recognizes that transformative, durable, and potentially curative gene therapies require innovative thinking about access, payment, and healthcare delivery.
